NASDAQ
21.11.25 | 21:59
79,56 US-Dollar
+3,35 % +2,58
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Mizuho initiates coverage on Tarsus Pharmaceuticals stock with Outperform rating | 1 | Investing.com | ||
| Do | Mizuho startet Coverage für Tarsus Pharmaceuticals mit "Outperform" und 30 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| Di | Aktie von Tarsus Pharmaceuticals klettert auf Rekordhoch von 76,85 USD | 2 | Investing.com Deutsch | ||
| 05.11. | Tarsus outlines $140M-$145M Q4 sales target while expanding XDEMVY adoption and pipeline progress | 2 | Seeking Alpha | ||
| 05.11. | Tarsus Q3 2025 presentation slides: XDEMVY sales surge 147% YoY to $118.7M | 2 | Investing.com | ||
| 04.11. | Tarsus Q3 2025: XDEMVY-Umsatz schnellt um 147 % auf 118,7 Mio. US-Dollar in die Höhe | 1 | Investing.com Deutsch | ||
| 04.11. | Tarsus Pharmaceuticals: Umsatz und Ergebnis übertreffen Prognosen für Q3 2025 | 2 | Investing.com Deutsch | ||
| TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 04.11. | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | 109 | GlobeNewswire (Europe) | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| 04.11. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.10. | Tarsus Pharmaceuticals, Inc: Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 | 1 | GlobeNewswire (USA) | ||
| 20.10. | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | 10 | Investing.com | ||
| 07.08. | Tarsus targets 95,000-100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum | 3 | Seeking Alpha | ||
| 06.08. | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | 479 | GlobeNewswire (Europe) | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| 06.08. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.08. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Tarsus Pharmaceuticals, Inc: Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | 1 | GlobeNewswire (USA) | ||
| 18.06. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 09.06. | Tarsus Pharmaceuticals auf Goldman Sachs Konferenz: Fokus auf strategisches Wachstum | 21 | Investing.com Deutsch | ||
| 02.06. | Oppenheimer assumes Tarsus stock at outperform on strong sales | 1 | Investing.com | ||
| 27.05. | Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 2 | Benzinga.com |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,206 | +0,58 % | Evotec: Startet jetzt der Turnaround? | ||
| MODERNA | 20,115 | -3,43 % | Biologische Fertigung im Fokus - wie NurExone, Moderna und Lonza von der Industrialisierung regenerativer Therapien profitieren könnten | ||
| VIKING THERAPEUTICS | 29,745 | +0,03 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity
Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| KUROS BIOSCIENCES | 28,840 | +0,14 % | Kuros erhöht nach den ersten neun Monaten das Umsatzziel | Schlieren - Das Medtechunternehmen Kuros zeigt sich nach den ersten neun Monaten zuversichtlicher betreffend der Umsatzentwicklung im Gesamtjahr 2025. Von Januar bis September erhöhte das Unternehmen... ► Artikel lesen | |
| ABIVAX | 103,20 | -0,19 % | Abivax gains amid takeover speculation | ||
| RELIEF THERAPEUTICS | 2,730 | -1,97 % | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Shareholders Approve Business Combination with NeuroX | Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
14-Nov-2025 / 18:20 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 1,927 | -1,15 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ||
| DENALI THERAPEUTICS | 15,660 | +0,22 % | Denali Therapeutics stock holds Buy rating at Stifel amid FDA review | ||
| CYTOMX THERAPEUTICS | 3,404 | +0,89 % | CytomX Therapeutics stock holds Overweight rating at Cantor Fitzgerald | ||
| ROCKET PHARMACEUTICALS | 2,560 | +0,79 % | Rocket Pharma cut at J.P. Morgan on risks to Danon disease program | ||
| SYNDAX PHARMACEUTICALS | 14,600 | -3,95 % | Syndax skizziert auf Jefferies-Konferenz Wachstumsstrategie für hämatologische Therapien | ||
| ASCENDIS PHARMA | 182,00 | -0,55 % | Ascendis Pharma: Results of Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics | COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH... ► Artikel lesen | |
| JASPER THERAPEUTICS | 1,700 | -3,95 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants | REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper"), a clinical-stage biotechnology company focused on development of briquilimab, a novel... ► Artikel lesen | |
| CHEMOMAB THERAPEUTICS | 2,490 | +2,47 % | Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer |
TARSUS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 79,56 Euro und damit +3,35 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.